SCHEMBL5129444

SCHEMBL5129444

CC(C)(CN)Oc1cc(Nc2ccnc3cc(C(F)(F)F)ccc23)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 7/20 0.57
RIPK2 O43353 5/20 0.49
COQ8A Q8NI60 3/20 0.49
NLK Q9UBE8 3/20 0.49
EPHB6 O15197 1/20 0.49
ABL1 P00519 1/20 0.49
LCK P06239 1/20 0.49
EPHA1 P21709 1/20 0.49
EPHA8 P29322 1/20 0.49
TXK P42681 1/20 0.49
CYP1A2 P05177 3/20 0.45
CYP2C8 P10632 3/20 0.45
CYP2D6 P10635 3/20 0.45
CYP2C19 P33261 3/20 0.45
CYP2C9 P11712 1/20 0.45
KCNH2 Q12809 1/20 0.42
AAK1 Q2M2I8 1/20 0.41
EGFR P00533 3/20 0.41
TGFBR1 P36897 1/20 0.40
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5123308 0.88 GAK (0.55) GAKCYP1A2CYP2C8CYP2D6CYP2C19
SCHEMBL4829985 0.81 GAK (0.57) GAKRIPK2COQ8ANLKEPHB6
SCHEMBL5126891 0.81 GAK (0.38) GAKRIPK2COQ8ANLKEPHB6
SCHEMBL29089850 0.73 GAK (0.65) GAKRIPK2COQ8ANLKEPHB6
SCHEMBL5132193 0.73 LMNA (0.51) GAAMAPT
SCHEMBL28845692 0.72 FADS1 (0.66) GAKRIPK2COQ8ANLKEPHB6
SCHEMBL29200468 0.71 GAK (0.61) GAKRIPK2COQ8ANLKEPHB6
SCHEMBL5929021 0.71 MAPT (0.69) GAKCYP1A2CYP2C8CYP2D6CYP2C19
SCHEMBL29200458 0.70 GAK (0.64) GAKRIPK2COQ8ANLKEPHB6
SCHEMBL29200480 0.70 GAK (0.57) GAKRIPK2COQ8ANLKEPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20050054850-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054850-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists UTS2R, GPR17, NTSR2 GAK 2544/4885RIPK2 1307/4885COQ8A 546/4885
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists UTS2R, GPR17, NTSR2 GAK 2544/4885RIPK2 1307/4885COQ8A 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.